

Jacob George

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6425328/publications.pdf>

Version: 2024-02-01

300
papers

29,462
citations

13827

67
h-index

5965

160
g-index

317
all docs

317
docs citations

317
times ranked

27041
citing authors

#	ARTICLE	IF	CITATIONS
1	Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 11-20.	8.2	3,487
2	The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. <i>Hepatology</i> , 2007, 45, 846-854.	3.6	2,448
3	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020, 73, 202-209.	1.8	2,171
4	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1999-2014.e1.	0.6	1,840
5	IL28B is associated with response to chronic hepatitis C interferon- α and ribavirin therapy. <i>Nature Genetics</i> , 2009, 41, 1100-1104.	9.4	1,808
6	Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2019, 69, 2672-2682.	3.6	1,203
7	The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 145-159.	8.2	571
8	Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 748-755.e3.	2.4	559
9	Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. <i>Gastroenterology</i> , 2018, 155, 443-457.e17.	0.6	536
10	Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. <i>PLoS Medicine</i> , 2014, 11, e1001680.	3.9	507
11	The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. <i>Hepatology International</i> , 2020, 14, 889-919.	1.9	422
12	Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. <i>Journal of Hepatology</i> , 2017, 67, 1204-1212.	1.8	390
13	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	8.2	330
14	Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. <i>Hepatology</i> , 2002, 36, 1266-1272.	3.6	323
15	Obesity Is a Risk Factor for Greater COVID-19 Severity. <i>Diabetes Care</i> , 2020, 43, e72-e74.	4.3	323
16	Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 167-228.	3.7	320
17	Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. <i>Journal of Hepatology</i> , 2017, 66, 142-152.	1.8	312
18	Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2020, 108, 154244.	1.5	281

#	ARTICLE	IF	CITATIONS
19	MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. <i>Liver International</i> , 2020, 40, 3018-3030.	1.9	274
20	Effect of aerobic exercise training dose on liver fat and visceral adiposity. <i>Journal of Hepatology</i> , 2015, 63, 174-182.	1.8	229
21	The changing epidemiology of liver diseases in the Asia-Pacific region. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 57-73.	8.2	221
22	Cytokines: From Clinical Significance to Quantification. <i>Advanced Science</i> , 2021, 8, e2004433.	5.6	216
23	Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. <i>Journal of Hepatology</i> , 2003, 39, 756-764.	1.8	215
24	Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection. <i>Gastroenterology</i> , 2015, 149, 1462-1470.	0.6	214
25	Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. <i>Hepatology</i> , 2020, 71, 1213-1227.	3.6	209
26	Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 40-52.	8.2	203
27	Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. <i>Hepatology</i> , 1995, 21, 120-128.	3.6	192
28	ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis. <i>Hepatology</i> , 2019, 69, 1075-1086.	3.6	174
29	Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. <i>Hepatology</i> , 1995, 21, 120-8.	3.6	172
30	Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. <i>Gut</i> , 2020, 69, 1545-1547.	6.1	166
31	Interferon-Î» rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. <i>Nature Communications</i> , 2015, 6, 6422.	5.8	156
32	Which patients with hepatitis C develop liver complications?. <i>Hepatology</i> , 2000, 31, 513-520.	3.6	149
33	Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1536-1543.	1.4	145
34	Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: implications for tumorigenesis, disease progression, and liver cancer stem cells. <i>Molecular Cancer</i> , 2017, 16, 165.	7.9	143
35	Genome-Wide Association Study Identifies Variants Associated With Progression of Liver Fibrosis From HCV Infection. <i>Gastroenterology</i> , 2012, 143, 1244-1252.e12.	0.6	142
36	Global multi-stakeholder endorsement of the MAFLD definition. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 388-390.	3.7	135

#	ARTICLE	IF	CITATIONS
37	Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019, 71, 1012-1021.	1.8	128
38	A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. <i>Journal of Hepatology</i> , 2014, 61, 1238-1246.	1.8	126
39	Patients with diabetes are at higher risk for severe illness from COVID-19. <i>Diabetes and Metabolism</i> , 2020, 46, 335-337.	1.4	124
40	Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 864-873.	3.7	123
41	Reply to: correspondence regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement". <i>Journal of Hepatology</i> , 2020, 73, 1575.	1.8	120
42	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2022, 76, 771-780.	1.8	114
43	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. <i>Gut</i> , 2022, 71, 382-390.	6.1	113
44	Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis. <i>Journal of Hepatology</i> , 2020, 73, 719-721.	1.8	112
45	Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1625-1633.e1.	2.4	107
46	Collagen biology and non-invasive biomarkers of liver fibrosis. <i>Liver International</i> , 2020, 40, 736-750.	1.9	107
47	Separate and Interactive Regulation of Cytochrome P450 3A4 by Triiodothyronine, Dexamethasone, and Growth Hormone in Cultured Hepatocytes ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2411-2416.	1.8	105
48	MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. <i>Nature Communications</i> , 2016, 7, 12757.	5.8	104
49	MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach. <i>Hepatology Research</i> , 2021, 51, 1115-1128.	1.8	104
50	A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma. <i>Hepatology</i> , 2018, 67, 216-231.	3.6	100
51	The Use of Nanoparticles to Deliver Nitric Oxide to Hepatic Stellate Cells for Treating Liver Fibrosis and Portal Hypertension. <i>Small</i> , 2015, 11, 2291-2304.	5.2	97
52	379 Characteristics and Long-Term Prognosis of Lean Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2014, 146, S-909.	0.6	94
53	The macrophage activation marker <i>CD163</i> is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2016, 36, 1549-1557.	1.9	94
54	Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 204-207.	1.4	91

#	ARTICLE	IF	CITATIONS
55	Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2320-2329.e12.	2.4	87
56	Exercise and ectopic fat in type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes and Metabolism</i> , 2017, 43, 195-210.	1.4	86
57	IFN- γ 3, not IFN- γ 4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. <i>Nature Genetics</i> , 2017, 49, 795-800.	9.4	86
58	Impact of common risk factors of fibrosis progression in chronic hepatitis C. <i>Gut</i> , 2015, 64, 1605-1615.	6.1	85
59	Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. <i>Hepatology</i> , 2016, 64, 34-46.	3.6	83
60	Aptamers: A promising chemical antibody for cancer therapy. <i>Oncotarget</i> , 2016, 7, 13446-13463.	0.8	82
61	Metabolic-associated fatty liver disease is associated with severity of COVID-19. <i>Liver International</i> , 2020, 40, 2160-2163.	1.9	80
62	From NAFLD to MAFLD: a redefining moment for fatty liver disease. <i>Chinese Medical Journal</i> , 2020, 133, 2271-2273.	0.9	79
63	Fatal outcome in a liver transplant recipient with COVID-19. <i>American Journal of Transplantation</i> , 2020, 20, 1907-1910.	2.6	77
64	The Geometric Framework for Nutrition as a tool in precision medicine. <i>Nutrition and Healthy Aging</i> , 2017, 4, 217-226.	0.5	76
65	Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. <i>Journal of Hepatology</i> , 2019, 71, 281-288.	1.8	76
66	Toward More Accurate Nomenclature for Fatty Liver Diseases. <i>Gastroenterology</i> , 2019, 157, 590-593.	0.6	75
67	The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. <i>Hepatology</i> , 2017, 65, 1840-1850.	3.6	74
68	Silencing of Jagged1 inhibits cell growth and invasion in colorectal cancer. <i>Cell Death and Disease</i> , 2014, 5, e1170-e1170.	2.7	70
69	Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 638-651.	8.2	69
70	Nonalcoholic Fatty Liver Disease: Pathogenesis and Potential for Nuclear Receptors as Therapeutic Targets. <i>Molecular Pharmaceutics</i> , 2008, 5, 49-59.	2.3	67
71	A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR. <i>Journal of Hepatology</i> , 2019, 70, 494-500.	1.8	67
72	FibroGENE: A gene-based model for staging liver fibrosis. <i>Journal of Hepatology</i> , 2016, 64, 390-398.	1.8	64

#	ARTICLE	IF	CITATIONS
73	Aptamers as targeting ligands and therapeutic molecules for overcoming drug resistance in cancers. <i>Advanced Drug Delivery Reviews</i> , 2018, 134, 107-121.	6.6	63
74	Liver Phenotypes of European Adults Heterozygous or Homozygous for Piâ—Z Variant of AAT (Piâ—MZ vs) Tj ETQq0,0 0 rgBT/Overlock	0.6	63
75	Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. <i>Hepatology International</i> , 2021, 15, 258-282.	1.9	62
76	Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 27-35.	4.6	60
77	Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 743-753.	3.7	60
78	The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study. <i>Journal of Hepatology</i> , 2018, 68, 393-401.	1.8	58
79	The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease. <i>Trends in Genetics</i> , 2020, 36, 429-441.	2.9	58
80	Host â€œ hepatitis C viral interactions: The role of genetics. <i>Journal of Hepatology</i> , 2016, 65, S22-S32.	1.8	57
81	Exercise and diet in the management of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1172-1182.	1.5	57
82	Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0155800.	1.1	54
83	Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients. <i>PLoS ONE</i> , 2015, 10, e0137302.	1.1	54
84	MAFLD enhances clinical practice for liver disease in the Asia-Pacific region. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 150-163.	4.5	53
85	Genetic Insights for Drug Development in NAFLD. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 506-516.	4.0	52
86	Aptamer-Based Therapeutic Approaches to Target Cancer Stem Cells. <i>Theranostics</i> , 2017, 7, 3948-3961.	4.6	51
87	The multifaceted and controversial immunometabolic actions of adiponectin. <i>Trends in Endocrinology and Metabolism</i> , 2014, 25, 444-451.	3.1	50
88	Adiponectin Reduces Hepatic Stellate Cell Migration by Promoting Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Secretion. <i>Journal of Biological Chemistry</i> , 2015, 290, 5533-5542.	1.6	50
89	Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection. <i>Gastroenterology</i> , 2015, 148, 355-366.e1.	0.6	49
90	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1456-e1468.	2.4	49

#	ARTICLE	IF	CITATIONS
91	Zinc is a potent and specific inhibitor of IFN- γ signalling. <i>Nature Communications</i> , 2017, 8, 15245.	5.8	47
92	Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 136-145.e6.	2.4	47
93	Genetic and epigenetic mechanisms of NASH. <i>Hepatology International</i> , 2016, 10, 394-406.	1.9	46
94	The Role of Micronutrients in the Infection and Subsequent Response to Hepatitis C Virus. <i>Cells</i> , 2019, 8, 603.	1.8	46
95	Experimental nonalcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic function. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, G295-G301.	1.6	44
96	Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. <i>Liver International</i> , 2017, 37, 1389-1396.	1.9	44
97	Macrophage Coordination of the Interferon Lambda Immune Response. <i>Frontiers in Immunology</i> , 2019, 10, 2674.	2.2	44
98	The benefits of exercise for patients with non-alcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1247-1250.	1.4	43
99	The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. <i>Journal of Gastroenterology</i> , 2018, 53, 679-688.	2.3	43
100	Diagnostic Accuracy of Noninvasive Fibrosis Scores in a Population of Individuals With a Low Prevalence of Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1453-1460.e1.	2.4	42
101	Serum Ferritin Levels Lack Diagnostic Accuracy for Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1163-1169.e1.	2.4	41
102	Adiponectin attenuates liver fibrosis by inducing nitric oxide production of hepatic stellate cells. <i>Journal of Molecular Medicine</i> , 2015, 93, 1327-1339.	1.7	41
103	Effect of Fish Oil Supplementation on Hepatic and Visceral Fat in Overweight Men: A Randomized Controlled Trial. <i>Nutrients</i> , 2019, 11, 475.	1.7	40
104	Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 268-277.	2.4	39
105	An aptamer-based drug delivery agent (CD133-apt-Dox) selectively and effectively kills liver cancer stem-like cells. <i>Cancer Letters</i> , 2021, 501, 124-132.	3.2	38
106	A systematic review and meta-analysis of HCV clearance. <i>Liver International</i> , 2017, 37, 1431-1445.	1.9	37
107	KLRG1+ natural killer cells exert a novel antifibrotic function in chronic hepatitis B. <i>Journal of Hepatology</i> , 2019, 71, 252-264.	1.8	37
108	Macrophages in metabolic associated fatty liver disease. <i>World Journal of Gastroenterology</i> , 2020, 26, 1861-1878.	1.4	37

#	ARTICLE	IF	CITATIONS
109	Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014). <i>Journal of Hepatology</i> , 2016, 65, 1086-1093.	1.8	36
110	IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. <i>Journal of Hepatology</i> , 2014, 61, 235-241.	1.8	35
111	Overcoming treatment resistance in cancer: Current understanding and tactics. <i>Cancer Letters</i> , 2017, 387, 69-76.	3.2	35
112	The antiviral role of zinc and metallothioneins in hepatitis C infection. <i>Journal of Viral Hepatitis</i> , 2018, 25, 491-501.	1.0	35
113	The nutritional geometry of liver disease including non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2018, 68, 316-325.	1.8	35
114	The Effect of a Novel Low-Volume Aerobic Exercise Intervention on Liver Fat in Type 2 Diabetes: A Randomized Controlled Trial. <i>Diabetes Care</i> , 2020, 43, 2371-2378.	4.3	35
115	Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2296-2306.e6.	2.4	35
116	Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19. <i>Diabetes and Metabolism</i> , 2020, 46, 505-507.	1.4	34
117	Community-based hepatitis B screening: what works?. <i>Hepatology International</i> , 2014, 8, 478-492.	1.9	33
118	Effect of resveratrol on experimental non-alcoholic steatohepatitis. <i>Pharmacological Research</i> , 2015, 95-96, 34-41.	3.1	33
119	Non-Obese MAFLD Is Associated with Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5462.	1.8	33
120	What Has the COVID-19 Pandemic Taught Us so Far? Addressing the Problem from a Hepatologist's Perspective. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 109-112.	0.7	33
121	Hepatitis C virus infection mediates cholesteryl ester synthesis to facilitate infectious particle production. <i>Journal of General Virology</i> , 2014, 95, 1900-1910.	1.3	32
122	Adiponectin confers protection from acute colitis and restricts a B cell immune response. <i>Journal of Biological Chemistry</i> , 2017, 292, 6569-6582.	1.6	32
123	A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD. <i>Scientific Reports</i> , 2018, 8, 10434.	1.6	32
124	The role of IFN in the development of NAFLD and NASH. <i>Cytokine</i> , 2019, 124, 154519.	1.4	31
125	An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 1240-1247.	1.2	30
126	Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors. <i>Cancer Letters</i> , 2017, 390, 188-200.	3.2	30

#	ARTICLE	IF	CITATIONS
127	The Epidemiology and Risk Factors of NASH. , 0, , 23-37.		29
128	Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study. <i>Journal of Hepatology</i> , 2016, 65, 879-887.	1.8	29
129	Fibrosis is not just fibrosis - basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 1242-1252.	1.9	29
130	Influence of clinicopathological variables on CYP protein expression in human liver. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1996, 11, 33-39.	1.4	28
131	Predicting the future burden of NAFLD and NASH. <i>Journal of Hepatology</i> , 2018, 69, 774-775.	1.8	28
132	A Mitochondrial Specific Antioxidant Reverses Metabolic Dysfunction and Fatty Liver Induced by Maternal Cigarette Smoke in Mice. <i>Nutrients</i> , 2019, 11, 1669.	1.7	28
133	Noncontrast MRI for Hepatocellular Carcinoma Detection: A Systematic Review and Meta-analysis â€œ A Potential Surveillance Tool?. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 44-56.e2.	2.4	28
134	Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 484-491.	1.4	27
135	High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia. <i>Journal of Hepatology</i> , 2021, 74, 293-302.	1.8	27
136	Developing liver organoids from induced pluripotent stem cells (iPSCs): An alternative source of organoid generation for liver cancer research. <i>Cancer Letters</i> , 2021, 508, 13-17.	3.2	27
137	Nonalcoholic Fatty Liver Disease Management: Dietary and Lifestyle Modifications. <i>Seminars in Liver Disease</i> , 2015, 35, 318-337.	1.8	26
138	Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2017, 77, 498-504.	0.6	26
139	HBV vaccination and HBV infection induces HBV-specific natural killer cell memory. <i>Gut</i> , 2021, 70, gutjnl-2019-319252.	6.1	26
140	Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates. <i>Oncologist</i> , 2021, 26, e1216-e1225.	1.9	26
141	Effect of resistance training on liver fat and visceral adiposity in adults with obesity: A randomized controlled trial. <i>Hepatology Research</i> , 2017, 47, 622-631.	1.8	25
142	The role of AdipoR1 and AdipoR2 in liver fibrosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 700-708.	1.8	25
143	COVID-19: The Immune Responses and Clinical Therapy Candidates. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5559.	1.8	25
144	Letter to the Editor: Obesity hypoventilation syndrome and severe COVID-19. <i>Metabolism: Clinical and Experimental</i> , 2020, 108, 154249.	1.5	25

#	ARTICLE	IF	CITATIONS
145	Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019. <i>Frontiers in Endocrinology</i> , 2021, 12, 604100.	1.5	25
146	Yet more evidence that MAFLD is more than a name change. <i>Journal of Hepatology</i> , 2021, 74, 977-979.	1.8	25
147	A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients. <i>American Journal of Gastroenterology</i> , 2021, 116, 984-993.	0.2	25
148	Role of human hepatic cytochromes P450 in drug metabolism and toxicity. <i>Australian and New Zealand Journal of Medicine</i> , 1991, 21, 356-362.	0.5	24
149	Genome-Wide Association Studies and Hepatitis C: Harvesting the Benefits of the Genomic Revolution. <i>Seminars in Liver Disease</i> , 2015, 35, 402-420.	1.8	24
150	Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 986-993.	0.6	23
151	Comparison of noninvasive models of fibrosis in chronic hepatitis B. <i>Hepatology International</i> , 2012, 6, 457-467.	1.9	22
152	Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012. <i>BMC Infectious Diseases</i> , 2018, 18, 215.	1.3	22
153	When a new definition overhauls perceptions of MAFLD related cirrhosis care. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 801-804.	0.7	22
154	Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1314-1322.	1.9	21
155	Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics. <i>Clinical Infectious Diseases</i> , 2021, 73, e3288-e3295.	2.9	21
156	Oct4 is a reliable marker of liver tumor propagating cells in hepatocellular carcinoma. <i>Discovery Medicine</i> , 2015, 20, 219-29.	0.5	21
157	Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host-targeting agents. <i>Journal of General Virology</i> , 2014, 95, 2468-2479.	1.3	20
158	Opposite associations between alanine aminotransferase and $\hat{\gamma}$ -glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 783-793.	1.5	20
159	Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C&CORAL study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 34, 12-21.	1.4	20
160	AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the \hat{A} BDL rat model. <i>Journal of Molecular Medicine</i> , 2019, 97, 423-434.	1.7	20
161	COVID-19 and liver transplantation: Lessons learned from three reported cases. <i>Transplant Infectious Disease</i> , 2020, 22, e13335.	0.7	20
162	Immunomodulation of the Natural Killer Cell Phenotype and Response during HCV Infection. <i>Journal of Clinical Medicine</i> , 2020, 9, 1030.	1.0	20

#	ARTICLE	IF	CITATIONS
163	ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. <i>Hepatology</i> , 2021, 73, 2238-2250.	3.6	20
164	Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent. <i>Genes and Immunity</i> , 2014, 15, 88-94.	2.2	19
165	Targeting IFN- γ : therapeutic implications. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 1425-1432.	1.5	19
166	Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study. <i>Journal of Viral Hepatitis</i> , 2018, 25, 473-481.	1.0	19
167	Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis. <i>Frontiers in Medicine</i> , 2020, 7, 615599.	1.2	19
168	Prevalence of elevated alanine transaminase in Australia and its relationship to metabolic risk factors: A cross-sectional study of 9,447 people. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 169-176.	1.4	18
169	The Australasian Psoriasis Collaboration view on methotrexate for psoriasis in the Australasian setting. <i>Australasian Journal of Dermatology</i> , 2017, 58, 166-170.	0.4	18
170	Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (^{MELD} \geq 15). <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 401-411.	1.9	18
171	Virus Genotype-Dependent Transcriptional Alterations in Lipid Metabolism and Inflammation Pathways in the Hepatitis C Virus-infected Liver. <i>Scientific Reports</i> , 2019, 9, 10596.	1.6	18
172	Targeting mTOR and Src restricts hepatocellular carcinoma growth in a novel murine liver cancer model. <i>PLoS ONE</i> , 2019, 14, e0212860.	1.1	18
173	Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD. <i>Metabolism: Clinical and Experimental</i> , 2022, 128, 154958.	1.5	18
174	Objectively Quantified Physical Activity and Sedentary Behavior in Predicting Visceral Adiposity and Liver Fat. <i>Journal of Obesity</i> , 2016, 2016, 1-10.	1.1	17
175	<p></p>Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma â€” A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients</p>. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 301-313.	1.8	17
176	A novel method to precisely quantify hepatitis B virus covalently closed circular (ccc)DNA formation and maintenance. <i>Antiviral Research</i> , 2020, 181, 104865.	1.9	17
177	The Effect of High-intensity Interval Training vs Moderate-intensity Continuous Training on Liver Fat: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 862-881.	1.8	17
178	Side effects are incompletely reported among systematic reviews in gastroenterology. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 144-153.	2.4	16
179	^{NAFLD} in clinical practice: Can simple blood and anthropometric markers be used to detect change in liver fat measured by ¹-MRS?. <i>Liver International</i> , 2017, 37, 1907-1915.	1.9	16
180	IFNL3 genotype is associated with pulmonary fibrosis in patients with systemic sclerosis. <i>Scientific Reports</i> , 2019, 9, 14834.	1.6	16

#	ARTICLE	IF	CITATIONS
181	Application of organoids in translational research of human diseases with a particular focus on gastrointestinal cancers. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1873, 188350.	3.3	16
182	E-cigarettes damage the liver and alter nutrient metabolism in pregnant mice and their offspring. <i>Annals of the New York Academy of Sciences</i> , 2020, 1475, 64-77.	1.8	16
183	Hepatitis C Virus Driven AXL Expression Suppresses the Hepatic Type I Interferon Response. <i>PLoS ONE</i> , 2015, 10, e0136227.	1.1	16
184	IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus pathogenesis. <i>Innate Immunity</i> , 2014, 20, 598-605.	1.1	15
185	Interferon-free regimens containing sofosbuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study. <i>Liver International</i> , 2016, 36, 505-514.	1.9	15
186	Immune responses to hepatitis B immunization 10-18 years after primary vaccination: a population-based cohort study. <i>Journal of Viral Hepatitis</i> , 2016, 23, 805-811.	1.0	15
187	Lean/normal-weight metabolic dysfunction-associated fatty liver disease is a risk factor for reflux esophagitis. <i>Hepatology Research</i> , 2022, 52, 699-711.	1.8	15
188	Biochemical markers of hepatic fibrogenesis: Single measurements are not reliable enough to replace liver biopsy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 819-821.	1.4	14
189	Elevated Liver Enzymes and Mortality in Older Individuals. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 439-445.	1.1	14
190	Hepatitis C Virus (HCV) Eradication With Interferon-Free Direct-Acting Antiviral-Based Therapy Results in KLRG1+ HCV-Specific Memory Natural Killer Cells. <i>Journal of Infectious Diseases</i> , 2021, 223, 1183-1195.	1.9	14
191	Cohort profile: golestan hepatitis B cohort study- a prospective long term study in northern iran. <i>Middle East Journal of Digestive Diseases</i> , 2014, 6, 186-94.	0.2	14
192	Single cell RNA-seq analysis identifies a noncoding RNA mediating resistance to sorafenib treatment in HCC. <i>Molecular Cancer</i> , 2022, 21, 6.	7.9	14
193	Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed <sc>LAM</sc>/<sc>ADV</sc> therapy. <i>Liver International</i> , 2017, 37, 827-835.	1.9	13
194	Reply to: Correspondence on "A new definition for metabolic associated fatty liver disease: an international expert consensus statement". <i>Journal of Hepatology</i> , 2020, 73, 1268-1269.	1.8	13
195	Role of the constitutive androstane receptor (CAR) in human liver cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188516.	3.3	13
196	Plasma Bile Acids More Closely Align With Insulin Resistance, Visceral and Hepatic Adiposity Than Total Adiposity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1131-e1139.	1.8	13
197	IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection. <i>Genes and Immunity</i> , 2016, 17, 328-334.	2.2	12
198	Role of BMP-9 in human liver disease. <i>Gut</i> , 2019, 68, 2097-2100.	6.1	12

#	ARTICLE	IF	CITATIONS
199	MAFLD: A holistic view to redefining fatty liver disease. <i>Journal of Hepatology</i> , 2021, 74, 983-985.	1.8	12
200	Core liver homeostatic co-expression networks are preserved but respond to perturbations in an organism- and disease-specific manner. <i>Cell Systems</i> , 2021, 12, 432-445.e7.	2.9	12
201	Expansion of dysfunctional CD56â€CD16+ NK cells in chronic hepatitis B patients. <i>Liver International</i> , 2021, 41, 969-981.	1.9	12
202	Metabolic (dysfunction) associated fatty liver disease: more evidence and a bright future. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 849-852.	0.7	12
203	The importance and impact of recognizing metabolic dysfunctionâ€associated fatty liver disease in patients with chronic hepatitis C. <i>Journal of Digestive Diseases</i> , 2022, 23, 33-43.	0.7	12
204	Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 204.	2.4	12
205	Physical and chemical insults induce inflammation and gastrointestinal cancers. <i>Cancer Letters</i> , 2014, 345, 190-195.	3.2	11
206	The Mechanism of Interferon Refractoriness During Hepatitis C Virus Infection and Its Reversal with a Peroxisome Proliferator-Activated Receptor Î± Agonist. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 488-497.	0.5	11
207	Factors associated with HBV Virological Breakthrough. <i>Antiviral Therapy</i> , 2017, 22, 53-60.	0.6	11
208	Real-World Efficacy and Safety of Ritonavir-Boosted Paritaprevir, Ombitasvir, Dasabuvir Â± Ribavirin for Hepatitis C Genotype 1 â€ Final Results of the REVITAL Study. <i>Antiviral Therapy</i> , 2017, 22, 699-710.	0.6	11
209	NAFLD: The evolving landscape. <i>Journal of Hepatology</i> , 2018, 68, 227-229.	1.8	11
210	A Sweet Connection? Fructoseâ€™s Role in Hepatocellular Carcinoma. <i>Biomolecules</i> , 2020, 10, 496.	1.8	11
211	Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. <i>EBioMedicine</i> , 2021, 70, 103521.	2.7	11
212	MAFLD and Cardiovascular Events: What Does the Evidence Show?. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2025-2028.	2.4	11
213	Liver-related effects of chronic hepatitis C antiviral treatment. <i>World Journal of Gastroenterology</i> , 2020, 26, 2931-2947.	1.4	11
214	A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 234-243.	1.9	11
215	Non-alcoholic fatty liver disease-related hepatocellular carcinoma: a sleeping tiger in the Asia Pacific. <i>Hepatology International</i> , 2013, 7, 823-832.	1.9	10
216	The Future Liver of the Asia Pacific: Fatter and Firmer from More Fructose and Fortune?. <i>Journal of Clinical and Experimental Hepatology</i> , 2013, 3, 106-113.	0.4	10

#	ARTICLE	IF	CITATIONS
217	Refining the role of epicardial adipose tissue in non-alcoholic fatty liver disease. <i>Hepatology International</i> , 2019, 13, 662-664.	1.9	10
218	Interferon- λ 3 Exacerbates the Inflammatory Response to Microbial Ligands: Implications for SARS-CoV-2 Pathogenesis. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 1257-1270.	1.6	10
219	Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus. <i>Advanced Science</i> , 2021, 8, 2004168.	5.6	10
220	Viral Biomarkers for Hepatitis B Virus-Related Hepatocellular Carcinoma Occurrence and Recurrence. <i>Frontiers in Microbiology</i> , 2021, 12, 665201.	1.5	10
221	Angiotensin-like proteins: Another player in the metabolic field. <i>Journal of Hepatology</i> , 2006, 44, 832-834.	1.8	9
222	Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertension. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 320-328.	1.9	9
223	Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 2037-2044.	2.9	9
224	Endotrophin, a pro-peptide of Type VI collagen, is a biomarker of survival in cirrhotic patients with hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2021, 8, HEP32.	4.2	9
225	Acute hepatitis A, B and C but not D is still prevalent in Mongolia: a time trend analysis. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 147-153.	4.5	9
226	Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection. <i>Liver International</i> , 2016, 36, 1774-1782.	1.9	8
227	Epidemiological Trends in NASH as a Cause for Liver Transplant. <i>Current Hepatology Reports</i> , 2016, 15, 67-74.	0.4	8
228	TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2017, 153, 1448-1449.	0.6	8
229	Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000-2014). <i>Hepatology Communications</i> , 2017, 1, 736-747.	2.0	8
230	Factors Associated with Non-Adherence to HBV Antiviral Therapy. <i>Antiviral Therapy</i> , 2018, 23, 425-433.	0.6	8
231	Interferon Lambda and Liver Fibrosis. <i>Journal of Interferon and Cytokine Research</i> , 2019, 39, 627-635.	0.5	8
232	Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 51-64.	1.4	8
233	Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival. <i>Journal of Viral Hepatitis</i> , 2021, 28, 710-718.	1.0	8
234	MAFLD: Now is the time to capitalize on the momentum. <i>Journal of Hepatology</i> , 2021, 74, 1262-1263.	1.8	8

#	ARTICLE	IF	CITATIONS
235	Hepatitis B and Liver Cancer: Community Awareness, Knowledge and Beliefs of Middle Eastern Migrants in Sydney, Australia. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8534.	1.2	8
236	Mitosis of hepatitis B virus-infected cells in vitro results in uninfected daughter cells. <i>JHEP Reports</i> , 2022, 4, 100514.	2.6	8
237	Predictors of liver-related complications in patients with chronic hepatitis C. <i>Annals of Medicine</i> , 2000, 32, 588-591.	1.5	7
238	A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF- β 1 dependent mechanisms. <i>Scientific Reports</i> , 2019, 9, 1439.	1.6	7
239	The effects of fructose and metabolic inhibition on hepatocellular carcinoma. <i>Scientific Reports</i> , 2020, 10, 16769.	1.6	7
240	Metabolic and genetic contributions to NAFLD: Really distinct and homogeneous?. <i>Journal of Hepatology</i> , 2022, 76, 498-500.	1.8	7
241	Low alanine aminotransferase levels and higher number of cardiovascular events in people with Type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. <i>Diabetic Medicine</i> , 2016, 33, 356-364.	1.2	6
242	Myeloid cell deletion of Aryl hydrocarbon Receptor Nuclear Translocator (ARNT) induces non-alcoholic steatohepatitis. <i>PLoS ONE</i> , 2019, 14, e0225332.	1.1	6
243	<i>rs35724</i> C variant modulates liver damage in nonalcoholic fatty liver disease. <i>Liver International</i> , 2021, 41, 2712-2719.	1.9	6
244	The prevalence of gestational diabetes mellitus in women diagnosed with non-alcoholic fatty liver disease during pregnancy: A systematic review and meta-analysis. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107991.	1.2	6
245	Efficacy and safety profile of calcineurin inhibitor salvage therapy in autoimmune hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 1309-1317.	0.6	5
246	Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	5
247	All-cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, . .	1.4	5
248	Updates in fatty liver disease: Pathophysiology, diagnosis and management. <i>Australian Journal of General Practice</i> , 2021, 50, 702-707.	0.3	5
249	Calsyntenin-1 mediates hepatitis C virus replication. <i>Journal of General Virology</i> , 2016, 97, 1877-1887.	1.3	5
250	Insulin Resistance in NAFLD: Potential Mechanisms and Therapies. , 0, , 38-54.		4
251	Reply:. <i>Hepatology</i> , 2005, 41, 401-402.	3.6	4
252	Reply:. <i>Hepatology</i> , 2008, 48, 1016-1017.	3.6	4

#	ARTICLE	IF	CITATIONS
253	The Burden of Non-alcoholic Fatty Liver Disease (NAFLD) in the Asia Pacific Region. <i>Current Hepatology Reports</i> , 2015, 14, 77-86.	0.4	4
254	Polymorphisms in STAT4 are not associated with treatment response and spontaneous clearance of hepatitis C virus in europeans. <i>Hepatology</i> , 2016, 64, 2264-2265.	3.6	4
255	Utilisation of hepatocellular carcinoma screening in Australians at risk of hepatitis B virus-related carcinoma and prescribed anti-viral therapy. <i>Journal of Clinical Nursing</i> , 2018, 27, 2673-2683.	1.4	4
256	Hepatic Aryl hydrocarbon Receptor Nuclear Translocator (ARNT) regulates metabolism in mice. <i>PLoS ONE</i> , 2017, 12, e0186543.	1.1	4
257	Pathology of Hepatic Steatosis, NASH and Related Conditions. , 0, , 13-22.		3
258	Nash As Part of the Metabolic (Insulin Resistance) Syndrome. , 0, , 55-65.		3
259	Animal Models of Steatohepatitis. , 0, , 91-108.		3
260	Ltb4r1 inhibitor: A pivotal insulin sensitizer?. <i>Trends in Endocrinology and Metabolism</i> , 2015, 26, 221-222.	3.1	3
261	Pre-treatment Antiviral Resistance in Australians with Chronic Hepatitis C: Prevalence of NS3 and NS5A Resistance Data in the State of New South Wales. <i>Antiviral Therapy</i> , 2019, 24, 281-290.	0.6	3
262	Pregnancy complicated by refractory severe hypercholaemia from sodium taurocholate co-transporting polypeptide deficiency. <i>Journal of Obstetrics and Gynaecology Research</i> , 2021, 47, 822-826.	0.6	3
263	The prevalence of metabolic associated fatty liver detected by FibroScan® in women with gestational diabetes in a multiethnic population. <i>Diabetes Research and Clinical Practice</i> , 2021, 174, 108757.	1.1	3
264	Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. <i>PLoS ONE</i> , 2020, 15, e0243590.	1.1	3
265	Aptamer-mediated doxorubicin delivery reduces HCC burden in 3D organoids model. <i>Journal of Controlled Release</i> , 2022, 341, 341-350.	4.8	3
266	Intra-familial Transmission of Chronic Hepatitis B Infection: A Large Population-Based Cohort Study in Northern Iran. <i>Archives of Iranian Medicine</i> , 2018, 21, 436-442.	0.2	3
267	COVID-19 Impact on Australian Patients with Substance Use Disorders: Emergency Department Admissions in Western Sydney before Vaccine Roll Out. <i>Vaccines</i> , 2022, 10, 889.	2.1	3
268	Impact of an intensive lifestyle program on low attenuation plaque and myocardial perfusion in coronary heart disease: A randomised clinical trial protocol. <i>Nutrition and Healthy Aging</i> , 2022, , 1-14.	0.5	3
269	Hepatitis C Virus Genotype 8 Infection- Successful Treatment With Sofosbuvir/Velpatasvir. <i>Journal of Infectious Diseases</i> , 2019, 220, 720-722.	1.9	2
270	MAFLD: A game changer redefining fatty liver disease for adults and children. <i>Journal of Hepatology</i> , 2021, 74, 992-994.	1.8	2

#	ARTICLE	IF	CITATIONS
271	Hep573 Study: A randomised, double-blind, placebo-controlled trial of silymarin alone and combined with antioxidants to improve liver function and quality of life in people with chronic hepatitis C. Australian Journal of Herbal and Naturopathic Medicine, 2019, 31, 64-76.	0.4	2
272	Client resistance to hepatitis C treatment initiation in opioid agonist treatment clinics in Sydney, Australia: A qualitative study. Drug and Alcohol Review, 2022, 41, 706-714.	1.1	2
273	Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort. Digestive Diseases and Sciences, 2023, 68, 291-303.	1.1	2
274	Cytokines and Inflammatory Recruitment in NASH: Experimental and Human Studies. , 0, , 123-131.		1
275	Cell Biology of NASH: Fibrosis and Cell Proliferation. , 0, , 143-158.		1
276	Management of NASH: Current and Future Perspectives on Treatment. , 0, , 194-207.		1
277	NAFLD, NASH and Orthotopic Liver Transplantation. , 0, , 208-217.		1
278	Steatohepatitis Resulting from Intestinal Bypass. , 0, , 241-248.		1
279	Specific Disorders Associated With NAFLD. , 0, , 249-262.		1
280	Oxidative stress is closely associated with insulin resistance in genotypes 1 and 3 chronic hepatitis C. Hepatology International, 2013, 7, 516-523.	1.9	1
281	NT-proBNP Changes in Patients with Ascites during Large Volume Paracentesis. ISRN Hepatology, 2013, 2013, 1-7.	0.9	1
282	Simeprevir with peginterferon α -2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study. BMC Infectious Diseases, 2017, 17, 389.	1.3	1
283	Editorial: STAT4 polymorphism â€•a tool to personalise clinical practice in chronic HBV infection. Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 769-770.	1.9	1
284	Community-Based Strategies to Improve Screening, Diagnosis and Linkage to Care for Patients with Chronic Hepatitis B. Current Hepatology Reports, 2019, 18, 342-356.	0.4	1
285	Clinical Cases in Hepatitis: Towards improving liver disease management in Australia. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 5-15.	1.4	1
286	Dual proteotoxic stress accelerates liver injury via activation of p62^{Nrf2} . Journal of Pathology, 2021, 254, 80-91.	2.1	1
287	Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. , 2018, 68, 349.		1
288	Managing the Patient with Chronic Viral Hepatitis Receiving Chemotherapy. , 2009, , 813-831.		1

#	ARTICLE	IF	CITATIONS
289	Colour Plate Section. , 0, , 320-323.		0
290	Clinical Manifestations and Diagnosis of NAFLD. , 0, , 159-167.		0
291	Reply:. Hepatology, 2007, 46, 2051-2051.	3.6	0
292	Reply:. Hepatology, 2008, 47, 761-761.	3.6	0
293	Preventing primary liver cancer: how well are we faring towards a national hepatitis B strategy?. Medical Journal of Australia, 2008, 189, 237-237.	0.8	0
294	Genetic and Epigenetic Associations of NAFLD: Focus on Clinical Decision Making. Current Hepatology Reports, 2017, 16, 335-345.	0.4	0
295	Editorial: weight change, liver histology and the metabolic effects of obeticholic acid in <scp>NASH</scp>. Alimentary Pharmacology and Therapeutics, 2018, 47, 1038-1039.	1.9	0
296	REPLY:. Hepatology, 2021, 74, 531-532.	3.6	0
297	Editorial: metformin for portal hypertensionâ€”old dog, new tricks? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 347-347.	1.9	0
298	Assoziation von rs16944 im Interleukin-1-beta-Gen mit der Entwicklung eines hepatozellulären Karzinoms in kaukasischen Patienten mit chronischer Virushepatitis. , 2020, 58, .		0
299	GeschlechtsabhÄngige Assoziation von genetischen Varianten von Interleukin 10 und 12 mit dem Verlauf der Hepatitis-B-Virus-Infektion bei kaukasischen Patienten. , 2020, 58, .		0
300	Obeticholic acid treatment in patients with non-alcoholic steatohepatitis: a secondary analysis of the REGENERATE study across fibrosis stages. , 2020, 58, .		0